Ironwood Pharma (IRWD) Tops Q3 EPS by 29c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Ironwood (IRWD) Updates on Q3 Activity; FDA Approves LINZESS, Linaclotide Gets Nod from CHMP
October 16, 2012 7:06 AM EDTIronwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today provided an update on its third quarter 2012 and recent business activities.
Third Quarter 2012 and Recent Highlights
LinaclotideThe U.S. Food and Drug Administration (FDA) approved LINZESS as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS can help to relieve abdominal pain and constipation associated with IBS-C, and constipation and hard stools associated with CIC. Ironwood and Forest Laboratories, Inc. expect LINZESS to be available to U.S. patients in... More
